Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Genzyme receives FDA orphan designation for anti-thymocyte globulin » 18:08
09/21/21
09/21
18:08
09/21/21
18:08
SNY

Sanofi

$48.24 /

+0.345 (+0.72%)

According to a post on…

According to a post on the FDA's website, Genzyme's anti-thymocyte globulin received orphan designation. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$48.24 /

+0.345 (+0.72%)

SNY Sanofi
$48.24 /

+0.345 (+0.72%)

09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
SNY Sanofi
$48.24 /

+0.345 (+0.72%)

SNY Sanofi
$48.24 /

+0.345 (+0.72%)

SNY Sanofi
$48.24 /

+0.345 (+0.72%)

Options
Four new option listings and eleven option delistings on September 21st » 08:30
09/21/21
09/21
08:30
09/21/21
08:30
BROS

Dutch Bros

$51.04 /

+7.505 (+17.24%)

, ONON

On Holding

$36.01 /

-2.99 (-7.67%)

, PUK

Prudential plc

$36.36 /

-3.589 (-8.98%)

, NRDY

Nerdy

$11.23 /

+0.07 (+0.63%)

, CBB

Cincinnati Bell

$15.49 /

+ (+0.00%)

, KIN

Kindred Biosciences

$9.25 /

+ (+0.00%)

, NWHM

New Home Company

$8.99 /

+ (+0.00%)

, ORBC

Taken private

$11.50 /

+ (+0.00%)

, PACE

TPG Pace Tech Opportunities

/

+

, PFPT

Proofpoint

$175.92 /

+ (+0.00%)

, QTS

QTS Realty Trust

$77.99 /

+ (+0.00%)

, SYKE

Sykes Enterprises

$53.99 /

+ (+0.00%)

, TBIO

Translate Bio

$37.37 /

+ (+0.00%)

, USCR

U.S. Concrete

$73.98 /

+ (+0.00%)

New option listings for…

New option listings for September 21st include BROS Stock (BROS), ONON Stock (ONON), Prudential Plc (PUK), and NRDY Stock (NRDY). Option delistings effective September 21st include CBB Stock (CBB), IPFF Stock (IPFF), KIN Stock (KIN), NWHM Stock (NWHM), ORBC Stock (ORBC), TPG Pace Tech Opportunities Corp (PACE), PFPT Stock (PFPT), QTS Stock (QTS), SYKE Stock (SYKE), Translate Bio Inc (TBIO), and USCR Stock (USCR).

ShowHide Related Items >><<
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

TBIO Translate Bio
$37.37 /

+ (+0.00%)

SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

PUK Prudential plc
$36.36 /

-3.589 (-8.98%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

PACE TPG Pace Tech Opportunities
/

+

ORBC Taken private
$11.50 /

+ (+0.00%)

ONON On Holding
$36.01 /

-2.99 (-7.67%)

NWHM New Home Company
$8.99 /

+ (+0.00%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

CBB Cincinnati Bell
$15.49 /

+ (+0.00%)

BROS Dutch Bros
$51.04 /

+7.505 (+17.24%)

BROS Dutch Bros
$51.04 /

+7.505 (+17.24%)

ONON On Holding
$36.01 /

-2.99 (-7.67%)

09/17/21 Citi
Deckers Brands portfolio being 'significantly undervalued,' says Citi
PUK Prudential plc
$36.36 /

-3.589 (-8.98%)

09/10/21 Barclays
Prudential plc price target raised to 1,733 GBp from 1,570 GBp at Barclays
09/08/21 Credit Suisse
Prudential plc price target raised to 1,800 GBp from 1,744 GBp at Credit Suisse
09/07/21 JPMorgan
Prudential plc price target raised to 1,523 GBp from 1,466 GBp at JPMorgan
08/23/21 BofA
Prudential plc upgraded to Buy from Neutral at BofA
NRDY Nerdy
$11.23 /

+0.07 (+0.63%)

05/26/21 Northland
TPG Pace Tech Opportunities initiated with an Outperform at Northland
CBB Cincinnati Bell
$15.49 /

+ (+0.00%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

08/23/21 Alliance Global Partners
Kindred downgraded to Neutral from Buy at Alliance Global Partners
06/18/21 Alliance Global Partners
Alliance Global keeps Buy rating on Kindred, thinks another bidder could emerge
06/17/21 Lake Street
Kindred Biosciences downgraded to Hold from Buy at Lake Street
06/17/21 H.C. Wainwright
Kindred Biosciences downgraded to Neutral from Buy at H.C. Wainwright
NWHM New Home Company
$8.99 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

05/11/21 Northland
Orbcomm downgraded to Market Perform from Outperform at Northland
05/10/21 Raymond James
Orbcomm downgraded to Underperform from Strong Buy at Raymond James
04/08/21 Raymond James
Orbcomm can terminate buyout with superior proposal, says Raymond James
04/08/21 Craig-Hallum
Orbcomm downgraded to Hold from Buy at Craig-Hallum
PACE TPG Pace Tech Opportunities
/

+

PFPT Proofpoint
$175.92 /

+ (+0.00%)

08/02/21 RBC Capital
Mimecast price target raised to $65 from $55 at RBC Capital
07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 JMP Securities
Proofpoint downgraded to Market Perform from Outperform at JMP Securities
05/24/21 Baird
Proofpoint downgraded to Neutral from Outperform at Baird
QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

06/10/21
Fly Intel: Top five analyst downgrades
06/10/21 Truist
QTS Realty Trust downgraded to Hold from Buy at Truist
06/09/21 Wells Fargo
QTS Realty Trust downgraded to Equal Weight at Wells Fargo
06/09/21 Wells Fargo
QTS Realty Trust downgraded to Equal Weight from Overweight at Wells Fargo
SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

06/21/21
Fly Intel: Top five analyst downgrades
06/21/21 Barrington
Sykes Enterprises downgraded to Market Perform from Outperform at Barrington
06/21/21 Baird
Sykes Enterprises downgraded to Neutral on takeout at Baird
06/21/21 Baird
Sykes Enterprises downgraded to Neutral from Outperform at Baird
TBIO Translate Bio
$37.37 /

+ (+0.00%)

08/04/21 Roth Capital
Translate Bio price target lowered to $38 from $45 at Roth Capital
08/03/21 B. Riley
Direct read to Arcturus from Translate Bio deal 'unwarranted,' says B. Riley
08/03/21 Brookline
Brookline reiterates Buy on Arcturus amid RNA focus following Translate Bio deal
08/03/21 Jefferies
Translate Bio downgraded to Hold from Buy at Jefferies
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

06/15/21 CJS Securities
U.S. Concrete downgraded to Market Perform from Outperform at CJS Securities
06/08/21 DA Davidson
U.S. Concrete price target raised to $74 from $55 at DA Davidson
04/14/21 Truist
U.S. Concrete price target raised to $65 from $35 at Truist
02/25/21 DA Davidson
U.S. Concrete price target raised to $50 from $30 at DA Davidson
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

TBIO Translate Bio
$37.37 /

+ (+0.00%)

SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

  • 15
    Sep
  • 15
    Sep
USCR U.S. Concrete
$73.98 /

+ (+0.00%)

TBIO Translate Bio
$37.37 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

TBIO Translate Bio
$37.37 /

+ (+0.00%)

SYKE Sykes Enterprises
$53.99 /

+ (+0.00%)

QTS QTS Realty Trust
$77.99 /

+ (+0.00%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

PACE TPG Pace Tech Opportunities
/

+

ORBC Taken private
$11.50 /

+ (+0.00%)

ONON On Holding
$36.01 /

-2.99 (-7.67%)

NRDY Nerdy
$11.23 /

+0.07 (+0.63%)

KIN Kindred Biosciences
$9.25 /

+ (+0.00%)

BROS Dutch Bros
$51.04 /

+7.505 (+17.24%)

USCR U.S. Concrete
$73.98 /

+ (+0.00%)

PUK Prudential plc
$36.36 /

-3.589 (-8.98%)

PFPT Proofpoint
$175.92 /

+ (+0.00%)

ORBC Taken private
$11.50 /

+ (+0.00%)

NWHM New Home Company
$8.99 /

+ (+0.00%)

CBB Cincinnati Bell
$15.49 /

+ (+0.00%)

Monday
Initiation
Denali Therapeutics initiated with an Outperform at Oppenheimer » 16:08
09/20/21
09/20
16:08
09/20/21
16:08
DNLI

Denali Therapeutics

$49.67 /

-3.15 (-5.96%)

, BIIB

Biogen

$297.90 /

-2.08 (-0.69%)

, SNY

Sanofi

$47.90 /

-0.445 (-0.92%)

, TAK

Takeda Pharmaceutical

$17.05 /

-0.115 (-0.67%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating and $85 price target. Given it has several late-stage candidates based on novel and differentiated mechanisms of action with "strong" preclinical and clinical data, Olson views Denali as an "underappreciated emerging leader in neurodegeneration and CNS disorders," he tells investors. He forecasts risk-adjusted peak total revenues of $8.76B in 2037 for Denali and views partnerships with "industry leaders" such as Biogen (BIIB), Sanofi (SNY) and Takeda (TAK) as providing external validation, the analyst added.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.05 /

-0.115 (-0.67%)

SNY Sanofi
$47.90 /

-0.445 (-0.92%)

DNLI Denali Therapeutics
$49.67 /

-3.15 (-5.96%)

BIIB Biogen
$297.90 /

-2.08 (-0.69%)

DNLI Denali Therapeutics
$49.67 /

-3.15 (-5.96%)

09/01/21 SMBC Nikko
Denali Therapeutics initiated with an Outperform at SMBC Nikko
07/26/21 Stifel
Denali DNL310 data 'noisy and trending in wrong direction,' says Stifel
07/26/21 H.C. Wainwright
Denali Therapeutics price target raised to $105 from $95 at H.C. Wainwright
05/18/21 UBS
Denali Therapeutics initiated with a Buy at UBS
BIIB Biogen
$297.90 /

-2.08 (-0.69%)

09/20/21 Piper Sandler
Neurologist survey shows Aduhelm 'rebounded sharply,' says Piper Sandler
09/16/21 UBS
Biogen price target lowered to $442 from $475 at UBS
09/15/21 BofA
Biogen price target lowered to $360 from $400 at BofA
09/09/21 Morgan Stanley
Morgan Stanley says Biogen challenges suggest low Aduhelm sales until NCD call
SNY Sanofi
$47.90 /

-0.445 (-0.92%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
TAK Takeda Pharmaceutical
$17.05 /

-0.115 (-0.67%)

08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
TAK Takeda Pharmaceutical
$17.05 /

-0.115 (-0.67%)

SNY Sanofi
$47.90 /

-0.445 (-0.92%)

DNLI Denali Therapeutics
$49.67 /

-3.15 (-5.96%)

BIIB Biogen
$297.90 /

-2.08 (-0.69%)

TAK Takeda Pharmaceutical
$17.05 /

-0.115 (-0.67%)

SNY Sanofi
$47.90 /

-0.445 (-0.92%)

BIIB Biogen
$297.90 /

-2.08 (-0.69%)

TAK Takeda Pharmaceutical
$17.05 /

-0.115 (-0.67%)

SNY Sanofi
$47.90 /

-0.445 (-0.92%)

DNLI Denali Therapeutics
$49.67 /

-3.15 (-5.96%)

BIIB Biogen
$297.90 /

-2.08 (-0.69%)

TAK Takeda Pharmaceutical
$17.05 /

-0.115 (-0.67%)

BIIB Biogen
$297.90 /

-2.08 (-0.69%)

Hot Stocks
Sanofi reports Libtayo Phase 3 trial met primary, key secondary endpoints » 06:38
09/20/21
09/20
06:38
09/20/21
06:38
SNY

Sanofi

$48.35 /

+0.14 (+0.29%)

, REGN

Regeneron

$651.38 /

-2.3 (-0.35%)

Phase 3 results for…

Phase 3 results for Sanofi (SNY) and Regeneron Pharmaceuticals' (REGN) Libtayo combination treatment were presented yesterday during a late-breaking session at the European Society for Medical Oncology Virtual Congress 2021. The trial, which met its primary overall survival endpoint and all key secondary endpoints, assessed the investigational use of PD-1 inhibitor Libtayo in combination with a physician's choice of platinum-doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, irrespective of histology and across all PD-L1 expression levels, compared to chemotherapy alone, Sanofi announced. These results were also achieved in a patient population with varied baseline characteristics and will form the basis of regulatory submissions, including in the U.S. and European Union. In the overall population, patients treated with the Libtayo combination experienced significant improvements compared to those receiving chemotherapy alone, including a: 22-month median OS compared to 13 months for chemotherapy, representing a 29% relative reduction in the risk of death. The 12-month probability of survival was 66% for the Libtayo combination and 56% for chemotherapy. 8-month median progression-free survival compared to 5 months for chemotherapy, representing a 46% relative reduction in the risk of disease progression . The 12-month probability of PFS was 38% for the Libtayo combination and 16% for chemotherapy. 43% objective response rate compared to 23% for chemotherapy. 16-month median duration of response compared to 7 months for chemotherapy.

ShowHide Related Items >><<
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
REGN Regeneron
$651.38 /

-2.3 (-0.35%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

REGN Regeneron
$651.38 /

-2.3 (-0.35%)

Recommendations
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote » 06:31
09/20/21
09/20
06:31
09/20/21
06:31
PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

, ABBV

AbbVie

$107.75 /

-0.33 (-0.31%)

, BMY

Bristol-Myers

$61.32 /

+0.1 (+0.16%)

, RHHBY

Roche

$46.07 /

-0.75 (-1.60%)

, NVO

Novo Nordisk

$101.45 /

-0.945 (-0.92%)

, SNY

Sanofi

$48.35 /

+0.14 (+0.29%)

Despite Friday's…

Despite Friday's mixed FDA panel decision on boosters, Citi analyst Andrew Baum argues that investors should "remain upbeat" over the outlook for Pfizer's (PFE) Covid-19 vaccine revenues. Near term, the analyst would not be surprised if the FDA "significantly broadened" the proposed population given economic and societal considerations. Mid-term, maturation of existing efficacy and datasets will likely expand the approval for annual boosters for the autumn/ fall months for future years, Baum tells investors in a research note. The analyst continues to see "significant upside" to near- and long-term Comirnaty consensus estimates. However, he keeps a Neutral rating on Pfizer with a $43 price target, preferring shares of AstraZeneca (AZN), AbbVie (ABBV), Bristol-Myers (BMY), Roche (Roche), Novo Nordisk (NVO) and Sanofi (SNY).

ShowHide Related Items >><<
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NVO Novo Nordisk
$101.45 /

-0.945 (-0.92%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
09/07/21 Morgan Stanley
Morgan Stanley cuts Vertex Pharmaceuticals to Underweight amid AbbVie overhang
BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
RHHBY Roche
$46.07 /

-0.75 (-1.60%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
NVO Novo Nordisk
$101.45 /

-0.945 (-0.92%)

09/03/21 Berenberg
Novo Nordisk price target raised to DKK 530 from DKK 430 at Berenberg
08/23/21 Credit Suisse
Novo Nordisk price target raised to DKK 625 from DKK 470 at Credit Suisse
08/23/21 Citi
Novo Nordisk price target raised to DKK 780 from DKK 510 at Citi
08/17/21 UBS
Novo Nordisk price target raised to DKK 630 from DKK 447 at UBS
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NVO Novo Nordisk
$101.45 /

-0.945 (-0.92%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RHHBY Roche
$46.07 /

-0.75 (-1.60%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NVO Novo Nordisk
$101.45 /

-0.945 (-0.92%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

BMY Bristol-Myers
$61.32 /

+0.1 (+0.16%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ABBV AbbVie
$107.75 /

-0.33 (-0.31%)

Over a week ago
Hot Stocks
Fly Intel: Top five weekend stock stories » 20:20
09/19/21
09/19
20:20
09/19/21
20:20
HMC

Honda

$30.98 /

-0.235 (-0.75%)

, F

Ford

$13.56 /

+0.16 (+1.19%)

, TM

Toyota

$180.91 /

-0.95 (-0.52%)

, GM

General Motors

$51.34 /

-0.18 (-0.35%)

, NSANY

Nissan

$10.37 /

-0.1415 (-1.35%)

, FUJHY

Subaru

$9.41 /

-0.085 (-0.90%)

, TSLA

Tesla

$759.92 /

+2.995 (+0.40%)

, RACE

Ferrari

$216.51 /

-2.4 (-1.10%)

, MZDAY

Mazda Motor

$4.30 /

-0.05 (-1.15%)

, DDAIF

Daimler AG

$83.55 /

-1.46 (-1.72%)

, BMWYY

BMW

$31.48 /

-0.905 (-2.79%)

, STLA

Stellantis

$19.78 /

-0.825 (-4.00%)

, TTM

Tata Motors

$20.68 /

-0.35 (-1.66%)

, GLBL

Cartesian Growth

$9.75 /

+0.05 (+0.52%)

, GILD

Gilead

$71.61 /

+0.34 (+0.48%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, MRK

Merck

$71.70 /

-0.25 (-0.35%)

, AVIR

Atea Pharmaceuticals

$26.23 /

-0.9 (-3.32%)

, DIS

Disney

$183.50 /

+0.205 (+0.11%)

, BHP

BHP Group

$55.53 /

-2.57 (-4.42%)

, RIO

Rio Tinto

$68.05 /

-2.1 (-2.99%)

, NGLOY

Anglo American

$18.06 /

-1.5899 (-8.09%)

, GLNCY

Glencore

$9.01 /

-0.17 (-1.85%)

, VALE

Vale

$16.30 /

-0.42 (-2.51%)

, NKE

Nike

$156.41 /

-1.21 (-0.77%)

, AAPL

Apple

$146.00 /

-2.84 (-1.91%)

, SNY

Sanofi

$48.35 /

+0.14 (+0.29%)

, WYNN

Wynn Resorts

$83.30 /

-1.095 (-1.30%)

, LVS

Las Vegas Sands

$38.17 /

+0.66 (+1.76%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. U.S. auto safety investigators have opened a new probe into 30 million vehicles built by nearly two dozen automakers with potentially defective Takata air bag inflators, Reuters' David Shepardson reported, citing a government document seen by the publication. The National Highway Traffic Safety Administration on Friday opened an engineering analysis into an estimated 30 million U.S. vehicles from the 2001 through 2019 model years, the author noted, adding that automakers were alerted to the investigation, which is not yet public. The new investigation includes vehicles assembled by Honda Motor (HMC), Ford Motor (F), Toyota Motor (TM), General Motors (GM), Nissan (NSANY), Subaru (FUJHY), Tesla (TSLA), Ferrari NV (RACE), Mazda (MZDAY), Daimler AG (DDAIF), BMW (BMWYY), Chrysler (STLA), Porsche Cars (POAHY), Jaguar Land Rover (TTM) and others. 2. Investment firms Tiedemann Group and Alvarium Investments are close to a deal to merge and go public through a special-purpose acquisition company, The Wall Street Journal's Amrith Ramkumar reported, citing people familiar with the matter. The combined investment firm would be called Alvarium Tiedemann Holdings and be valued at roughly $1.4 billion in the deal with the SPAC Cartesian Growth Corp. (GLBL), the people said. The merger could be announced as soon as this week, the author noted. 3. In the earliest days of COVID-19 pandemic, investor and drug developers looked to antivirals to blunt the impact of the disease but didn't have much luck, with the only antiviral authorized by the Food and Drug Administration to date being Gilead's (GILD) Veklury, also known as remdesivir, Josh Nathan-Kazis wrote in this week's edition of Barron's. But the next generation of COVID-19 antivirals are now on the way, and a pill to treat - or even prevent - COVID-19 could be available by the end of the year. Merck (MRK), Pfizer (PFE), and the biotech Atea Pharmaceuticals (AVIR) each expect late-stage data on an oral COVID-19 antiviral in the coming months. If the data are positive, the drugs provide a major opportunity for the companies-one that investors should not ignore, the author noted. 4. Disney's (DIS) "Shang-Chi and the Legend of the Ten Rings" remained atop the box office charts in its third weekend, earning an estimated $21.7M from 4,070 theaters for a total North American ticket sales of $176.9M. The superhero movie sports an A Cinemascore and unlike fellow Marvel Studios pic "Black Widow," "Shang-Chi" has an exclusive 45-day theatrical release. 5. Apple (AAPL), Sanofi (SNY), BHP Group (BHP), Rio Tinto (RIO), Anglo American (NGLOY), Glencore (GLNCY), Vale (VALE), Wynn Resorts (WYNN) and Las Vegas Sands (LVS) saw positive mentions in this week's edition of Barron's, while Nike (NKE) was mentioned cautiously.

ShowHide Related Items >><<
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

TTM Tata Motors
$20.68 /

-0.35 (-1.66%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TM Toyota
$180.91 /

-0.95 (-0.52%)

STLA Stellantis
$19.78 /

-0.825 (-4.00%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

RACE Ferrari
$216.51 /

-2.4 (-1.10%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NSANY Nissan
$10.37 /

-0.1415 (-1.35%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

MZDAY Mazda Motor
$4.30 /

-0.05 (-1.15%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

HMC Honda
$30.98 /

-0.235 (-0.75%)

GM General Motors
$51.34 /

-0.18 (-0.35%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

F Ford
$13.56 /

+0.16 (+1.19%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

DDAIF Daimler AG
$83.55 /

-1.46 (-1.72%)

BMWYY BMW
$31.48 /

-0.905 (-2.79%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

HMC Honda
$30.98 /

-0.235 (-0.75%)

02/18/21 Daiwa
Honda downgraded to Outperform from Buy at Daiwa
F Ford
$13.56 /

+0.16 (+1.19%)

09/08/21 Benchmark
Worst of chip shortage could be over for Ford, says Benchmark
07/16/21 BofA
Ford price target raised to $18 from $17 at BofA
06/29/21 UBS
Ford price target raised to $16 from $13 at UBS
06/22/21 Barclays
Ford price target raised to $17 from $15 at Barclays
TM Toyota
$180.91 /

-0.95 (-0.52%)

09/16/21 Morgan Stanley
XPeng 'aiming to redefine mass-market EVs' with P5, says Morgan Stanley
03/30/21 Citi
Toyota resumed with a Buy at Citi
GM General Motors
$51.34 /

-0.18 (-0.35%)

09/13/21 Barclays
General Motors price target lowered to $68 from $71 at Barclays
08/09/21 Jefferies
General Motors price target lowered to $53 from $68 at Jefferies
08/05/21 JPMorgan
GM post-earnings selloff 'seems overblown,' says JPMorgan
08/05/21 Deutsche Bank
General Motors investors should look past headwinds, says Deutsche Bank
NSANY Nissan
$10.37 /

-0.1415 (-1.35%)

07/29/21 CLSA
Nissan upgraded to Buy from Underperform at CLSA
02/16/21 Wedbush
Wedbush expects Apple to announce formal EV partnership in 2021
12/21/20 SMBC Nikko
Nissan upgraded to Neutral from Underperform at SMBC Nikko
10/28/20 Jefferies
Nissan upgraded to Hold from Underperform at Jefferies
FUJHY Subaru
$9.41 /

-0.085 (-0.90%)

03/17/21 Goldman Sachs
Subaru downgraded to Neutral from Buy at Goldman Sachs
TSLA Tesla
$759.92 /

+2.995 (+0.40%)

09/17/21 Morgan Stanley
520 mile EPA range 'an important milestone' for Lucid, says Morgan Stanley
09/17/21 Wedbush
Tesla EV demand story just starting to play out, says Wedbush
09/15/21 BofA
BofA calls Lucid the 'Tesla/Ferrari of new EV automakers,' starts at Buy
09/10/21 Craig-Hallum
VIA Optronics price target lowered to $14 from $18 at Craig-Hallum
RACE Ferrari
$216.51 /

-2.4 (-1.10%)

09/16/21 Exane BNP Paribas
Ferrari cut to Neutral at Exane BNP Paribas on slow cyclical recovery
09/16/21 Exane BNP Paribas
Ferrari downgraded to Neutral from Outperform at Exane BNP Paribas
09/09/21 Oddo BHF
Ferrari initiated with an Outperform at Oddo BHF
MZDAY Mazda Motor
$4.30 /

-0.05 (-1.15%)

08/17/21 Credit Suisse
Mazda Motor upgraded to Neutral from Underperform at Credit Suisse
06/24/21 UBS
Mazda Motor upgraded to Buy from Sell at UBS
10/13/20 Citi
Mazda Motor upgraded to Neutral from Sell at Citi
DDAIF Daimler AG
$83.55 /

-1.46 (-1.72%)

09/17/21 JPMorgan
Daimler AG price target lowered to EUR 98 from EUR 100 at JPMorgan
08/11/21 Barclays
Daimler AG price target lowered to EUR 110 from EUR 115 at Barclays
08/09/21 Jefferies
Daimler AG downgraded to Hold from Buy at Jefferies
08/01/21 Goldman Sachs
Daimler AG upgraded to Conviction Buy from Buy at Goldman Sachs
BMWYY BMW
$31.48 /

-0.905 (-2.79%)

09/17/21 JPMorgan
BMW price target lowered to EUR 88 from EUR 95 at JPMorgan
09/15/21 Deutsche Bank
BMW named short-term investment idea at Deutsche Bank
08/20/21 Erste Group
BMW downgraded to Hold from Buy at Erste Group
08/11/21 Barclays
BMW price target lowered to EUR 95 from EUR 108 at Barclays
STLA Stellantis
$19.78 /

-0.825 (-4.00%)

09/07/21 KeyBanc
Jeep micro site on Amazon points to auto sales moving online, says KeyBanc
09/03/21 Deutsche Bank
Stellantis deal 'significant opportunity' for Open Lending, says Deutsche Bank
09/02/21 DA Davidson
DA Davidson says Stellantis opportunity for Open Lending not 'fait accompli'
09/02/21 Raymond James
Raymond James says buy Open Lending aggressively after Stellantis deal
TTM Tata Motors
$20.68 /

-0.35 (-1.66%)

06/30/21 Jefferies
Tata Motors assumed with a Buy at Jefferies
06/29/21 Nomura
Tata Motors upgraded to Neutral from Reduce at Nomura
02/05/21 UBS
Tata Motors upgraded to Neutral from Sell at UBS
GLBL Cartesian Growth
$9.75 /

+0.05 (+0.52%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
MRK Merck
$71.70 /

-0.25 (-0.35%)

09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

09/09/21 SVB Leerink
Atea Pharmaceuticals initiated with an Outperform at SVB Leerink
04/16/21 William Blair
Atea selloff on Merck update unwarranted, says William Blair
01/29/21 JPMorgan
Atea Pharmaceuticals price target raised to $66 from $45 at JPMorgan
11/24/20 Evercore ISI
Atea Pharmaceuticals initiated with an Outperform at Evercore ISI
DIS Disney
$183.50 /

+0.205 (+0.11%)

09/13/21 Stephens
Recent Apple TV+ news positive for Roku, says Stephens
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
09/09/21 Arete
Disney initiated with a Buy at Arete
08/30/21 JPMorgan
Movie executives see 10% of screens closing, down from 15%, says JPMorgan
BHP BHP Group
$55.53 /

-2.57 (-4.42%)

09/14/21 Barclays
BHP Group downgraded to Equal Weight from Overweight at Barclays
08/18/21 RBC Capital
BHP Group price target lowered to 2,300 GBp from 2,400 GBp at RBC Capital
07/30/21 CLSA
Rio Tinto downgraded to Sell from Underperform at CLSA
07/08/21 Berenberg
BHP Group upgraded to Buy from Hold at Berenberg
RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

09/17/21 Morgan Stanley
Rio Tinto price target lowered to 5,410 GBp from 6,330 GBp at Morgan Stanley
09/17/21 UBS
Rio Tinto price target lowered to A$86 from A$102 at UBS
09/16/21 Deutsche Bank
Rio Tinto price target lowered to 6,000 GBp from 6,600 GBp at Deutsche Bank
09/14/21 Barclays
Rio Tinto price target lowered to 4,900 GBp from 6,000 GBp at Barclays
NGLOY Anglo American
$18.06 /

-1.5899 (-8.09%)

09/17/21 Morgan Stanley
Anglo American downgraded to Equal Weight from Overweight at Morgan Stanley
09/17/21 UBS
Anglo American downgraded to Sell from Neutral at UBS
09/16/21 Deutsche Bank
Anglo American price target lowered to 3,600 GBp at Deutsche Bank
09/14/21 Barclays
Anglo American price target lowered to 3,600 GBp from 3,700 GBp at Barclays
GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

09/17/21 Morgan Stanley
Glencore upgraded to Overweight from Equal Weight at Morgan Stanley
09/16/21 RBC Capital
Glencore price target raised to 400 GBp from 360 GBp at RBC Capital
09/16/21 Deutsche Bank
Glencore price target raised to 440 GBp from 420 GBp at Deutsche Bank
09/16/21 RBC Capital
Glencore price target raised to 400 GBp from 360 GBp at RBC Capital
VALE Vale
$16.30 /

-0.42 (-2.51%)

09/17/21 UBS
Vale downgraded to Sell from Buy at UBS
07/15/21 HSBC
Vale price target raised to $27 from $25 at HSBC
07/12/21 Scotiabank
Vale price target raised to $26 from $24 at Scotiabank
07/02/21 RBC Capital
Vale price target lowered to $27 from $29 at RBC Capital
NKE Nike
$156.41 /

-1.21 (-0.77%)

09/13/21
Fly Intel: Top five analyst downgrades
09/13/21 BTIG
BTIG downgrades Nike on 'severe supply chain disruptions' in Vietnam
09/13/21 BTIG
Nike downgraded to Neutral from Buy at BTIG
09/09/21 UBS
Nike more likely to rise than fall after Q1 results, says UBS
AAPL Apple
$146.00 /

-2.84 (-1.91%)

09/17/21 Jefferies
Snap Q3 revenue estimates too low, says Jefferies
09/15/21 Oppenheimer
Apple's iPhone 13 likely to attract upgraders, says Oppenheimer
09/15/21 Deutsche Bank
Apple iPhone changes 'more incremental than transformative,' says Deutsche Bank
09/15/21 Morgan Stanley
Improved iPhone affordability raises Morgan Stanley confidence in Apple growth
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

09/17/21
Fly Intel: Top five analyst downgrades
09/17/21 Argus
Wynn Resorts downgraded to Hold from Buy at Argus
09/17/21 Argus
Wynn Resorts downgraded to Hold from Buy at Argus
09/16/21 JPMorgan
Wynn Resorts downgraded on Macau uncertainty at JPMorgan
LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

09/17/21 Jefferies
Jefferies downgrades Las Vegas Sands on 'growth uncertainty' in Macau
09/17/21 Jefferies
Las Vegas Sands downgraded to Hold from Buy at Jefferies
09/16/21 JPMorgan
JPMorgan downgrades Las Vegas Sands on Macau uncertainty
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TM Toyota
$180.91 /

-0.95 (-0.52%)

STLA Stellantis
$19.78 /

-0.825 (-4.00%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RACE Ferrari
$216.51 /

-2.4 (-1.10%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

HMC Honda
$30.98 /

-0.235 (-0.75%)

GM General Motors
$51.34 /

-0.18 (-0.35%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

F Ford
$13.56 /

+0.16 (+1.19%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

DDAIF Daimler AG
$83.55 /

-1.46 (-1.72%)

BMWYY BMW
$31.48 /

-0.905 (-2.79%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

  • 09
    Feb
  • 30
    Oct
WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

TTM Tata Motors
$20.68 /

-0.35 (-1.66%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TM Toyota
$180.91 /

-0.95 (-0.52%)

STLA Stellantis
$19.78 /

-0.825 (-4.00%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

RACE Ferrari
$216.51 /

-2.4 (-1.10%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NSANY Nissan
$10.37 /

-0.1415 (-1.35%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

HMC Honda
$30.98 /

-0.235 (-0.75%)

GM General Motors
$51.34 /

-0.18 (-0.35%)

GLNCY Glencore
$9.01 /

-0.17 (-1.85%)

GLBL Cartesian Growth
$9.75 /

+0.05 (+0.52%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

F Ford
$13.56 /

+0.16 (+1.19%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

DDAIF Daimler AG
$83.55 /

-1.46 (-1.72%)

BMWYY BMW
$31.48 /

-0.905 (-2.79%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TM Toyota
$180.91 /

-0.95 (-0.52%)

STLA Stellantis
$19.78 /

-0.825 (-4.00%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

RACE Ferrari
$216.51 /

-2.4 (-1.10%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NSANY Nissan
$10.37 /

-0.1415 (-1.35%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

HMC Honda
$30.98 /

-0.235 (-0.75%)

GM General Motors
$51.34 /

-0.18 (-0.35%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

F Ford
$13.56 /

+0.16 (+1.19%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

DDAIF Daimler AG
$83.55 /

-1.46 (-1.72%)

BMWYY BMW
$31.48 /

-0.905 (-2.79%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

AVIR Atea Pharmaceuticals
$26.23 /

-0.9 (-3.32%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

WYNN Wynn Resorts
$83.30 /

-1.095 (-1.30%)

VALE Vale
$16.30 /

-0.42 (-2.51%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TM Toyota
$180.91 /

-0.95 (-0.52%)

RIO Rio Tinto
$68.05 /

-2.1 (-2.99%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

NKE Nike
$156.41 /

-1.21 (-0.77%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

LVS Las Vegas Sands
$38.17 /

+0.66 (+1.76%)

GM General Motors
$51.34 /

-0.18 (-0.35%)

GILD Gilead
$71.61 /

+0.34 (+0.48%)

F Ford
$13.56 /

+0.16 (+1.19%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

BHP BHP Group
$55.53 /

-2.57 (-4.42%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

AAPL Apple
$146.00 /

-2.84 (-1.91%)

Periodicals
COVID vaccine could lift Sanofi stock, Barron's says » 10:04
09/18/21
09/18
10:04
09/18/21
10:04
SNY

Sanofi

$48.35 /

+0.14 (+0.29%)

, PFE

Pfizer

$43.89 /

-0.57 (-1.28%)

, AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

, GSK

GlaxoSmithKline

$38.94 /

-0.16 (-0.41%)

Few Big Pharma companies…

Few Big Pharma companies have proved able to catch the early wave of COVID-19 vaccines and ride it to success. But Sanofi (SNY) is trying hard to show that there is a life after failure-or, as the company would prefer to put it, setback, Pierre Briancon writes in this week's edition of Barron's. While rivals Pfizer (PFE) and AstraZeneca (AZN) showed potential of cross-cooperation with smaller, nimbler partners in developing and producing vaccines against the new virus in record time, for Sanofi and partner GlaxoSmithKline (GSK), it looked more like a process of hits and misses, with a series of setbacks leading to a vaccine delay, the author notes. The jab is now in its Phase 3 trial, and Sanofi spokesman Nicolas Kressmann says the company has a good chance of producing its results "before the end of the last quarter at the earliest," which means that if everything goes according to plan, regulators the world over will then approve it for distribution within days. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
PFE Pfizer
$43.89 /

-0.57 (-1.28%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
08/19/21 Berenberg
GlaxoSmithKline price target raised to 1,625 GBp from 1,570 GBp at Berenberg
SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

SNY Sanofi
$48.35 /

+0.14 (+0.29%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

PFE Pfizer
$43.89 /

-0.57 (-1.28%)

GSK GlaxoSmithKline
$38.94 /

-0.16 (-0.41%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Conference/Events
BofA to hold a virtual conference » 04:55
09/17/21
09/17
04:55
09/17/21
04:55
RHHBY

Roche

$46.82 /

-0.04 (-0.09%)

, ALLO

Allogene Therapeutics

$24.53 /

-0.42 (-1.68%)

, ATR

AptarGroup

$122.29 /

-2.415 (-1.94%)

, FMS

Fresenius Medical

$35.31 /

-0.36 (-1.01%)

, SNY

Sanofi

$48.20 /

+0.185 (+0.39%)

, WAT

Waters

$399.60 /

-10.23 (-2.50%)

, ALNY

Alnylam

$190.23 /

+2.63 (+1.40%)

, BLUE

Bluebird Bio

$17.67 /

-0.12 (-0.67%)

, AZN

AstraZeneca

$56.60 /

+0.14 (+0.25%)

, EXEL

Exelixis

$20.53 /

+0.04 (+0.20%)

, FOLD

Amicus

$11.09 /

-0.06 (-0.54%)

, PFE

Pfizer

$44.46 /

-0.31 (-0.69%)

, PAHC

Phibro Animal Health

$21.32 /

-0.08 (-0.37%)

, QGEN

Qiagen

$54.15 /

+0.6601 (+1.23%)

, IONS

Ionis Pharmaceuticals

$36.45 /

-0.55 (-1.49%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference to be held on September 15-17.

ShowHide Related Items >><<
WAT Waters
$399.60 /

-10.23 (-2.50%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

08/06/21 B. Riley
Allogene Therapeutics price target lowered to $40 from $52 at B. Riley
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

09/13/21 Baird
AptarGroup price target lowered to $135 from $150 at Baird
08/02/21 William Blair
William Blair downgrades AptarGroup after 'underwhelming quarter'
08/02/21 William Blair
AptarGroup downgraded to Market Perform from Outperform at William Blair
04/19/21 Deutsche Bank
AptarGroup price target raised to $162 from $152 at Deutsche Bank
FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

09/10/21 Barclays
Fresenius Medical downgraded to Equal Weight from Overweight at Barclays
09/10/21 JPMorgan
Fresenius Medical downgraded to Underweight from Neutral at JPMorgan
08/11/21 JPMorgan
Fresenius Medical price target raised to EUR 61.30 from EUR 58.80 at JPMorgan
08/04/21 Societe Generale
Fresenius Medical price target raised to EUR 71 from EUR 64 at Societe Generale
SNY Sanofi
$48.20 /

+0.185 (+0.39%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
WAT Waters
$399.60 /

-10.23 (-2.50%)

08/04/21 SVB Leerink
Waters price target raised to $385 from $370 at SVB Leerink
08/04/21 Baird
Waters price target raised to $360 from $297 at Baird
08/04/21 Citi
Waters price target raised to $400 from $315 at Citi
07/06/21 Evercore ISI
Evercore ISI upgrades Waters to Outperform on turnaround progress
ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

08/27/21 BMO Capital
Alnylam price target raised to $196 from $174 at BMO Capital
08/04/21 Barclays
Alnylam price target raised to $216 from $196 at Barclays
08/04/21 Piper Sandler
Alnylam downgraded to Neutral from Overweight at Piper Sandler
06/30/21 Piper Sandler
Alnylam's zilebesiran has 'best in class' potential, says Piper Sandler
BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
08/10/21 Canaccord
Bluebird Bio downgraded to Hold from Buy at Canaccord
08/10/21 Mizuho
Bluebird Bio price target lowered to $29 from $70 at Mizuho
AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
FOLD Amicus
$11.09 /

-0.06 (-0.54%)

07/19/21 BTIG
Amicus assumed with a Buy at BTIG
07/09/21 Chardan
Amicus coverage transferred at Chardan
07/01/21 Berenberg
Amicus assumed with a Hold at Berenberg
05/27/21 Needham
Amicus initiated with a Hold at Needham
PFE Pfizer
$44.46 /

-0.31 (-0.69%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
PAHC Phibro Animal Health
$21.32 /

-0.08 (-0.37%)

08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
07/07/21 Barclays
Phibro Animal Health downgraded to Underweight from Equal Weight at Barclays
QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

07/14/21 Citi
Qiagen price target lowered to $58 from $65 at Citi
07/14/21 Kepler Cheuvreux
Qiagen downgraded to Hold from Buy at Kepler Cheuvreux
06/11/21 Berenberg
Qiagen price target lowered to EUR 54 from EUR 56 at Berenberg
06/03/21 Goldman Sachs
Qiagen initiated with a Neutral at Goldman Sachs
IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
WAT Waters
$399.60 /

-10.23 (-2.50%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

PAHC Phibro Animal Health
$21.32 /

-0.08 (-0.37%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

Conference/Events
BofA to hold a virtual conference » 10:13
09/16/21
09/16
10:13
09/16/21
10:13
RHHBY

Roche

$46.86 /

+0.11 (+0.24%)

, ALLO

Allogene Therapeutics

$24.58 /

-0.37 (-1.48%)

, ATR

AptarGroup

$123.60 /

-1.1 (-0.88%)

, FMS

Fresenius Medical

$35.25 /

-0.42 (-1.18%)

, SNY

Sanofi

$48.22 /

+0.21 (+0.44%)

, WAT

Waters

$407.50 /

-2.335 (-0.57%)

, ALNY

Alnylam

$188.20 /

+0.595 (+0.32%)

, BLUE

Bluebird Bio

$17.50 /

-0.29 (-1.63%)

, AZN

AstraZeneca

$56.25 /

-0.21 (-0.37%)

, EXEL

Exelixis

$20.31 /

-0.18 (-0.88%)

, FOLD

Amicus

$11.02 /

-0.13 (-1.17%)

, PFE

Pfizer

$44.71 /

-0.06 (-0.13%)

, PAHC

Phibro Animal Health

$21.37 /

-0.03 (-0.14%)

, QGEN

Qiagen

$53.51 /

+0.02 (+0.04%)

, IONS

Ionis Pharmaceuticals

$36.23 /

-0.77 (-2.08%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference to be held on September 15-17.

ShowHide Related Items >><<
WAT Waters
$407.50 /

-2.335 (-0.57%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

FOLD Amicus
$11.02 /

-0.13 (-1.17%)

FMS Fresenius Medical
$35.25 /

-0.42 (-1.18%)

EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

ATR AptarGroup
$123.60 /

-1.1 (-0.88%)

ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

08/06/21 B. Riley
Allogene Therapeutics price target lowered to $40 from $52 at B. Riley
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
ATR AptarGroup
$123.60 /

-1.1 (-0.88%)

09/13/21 Baird
AptarGroup price target lowered to $135 from $150 at Baird
08/02/21 William Blair
William Blair downgrades AptarGroup after 'underwhelming quarter'
08/02/21 William Blair
AptarGroup downgraded to Market Perform from Outperform at William Blair
04/19/21 Deutsche Bank
AptarGroup price target raised to $162 from $152 at Deutsche Bank
FMS Fresenius Medical
$35.25 /

-0.42 (-1.18%)

09/10/21 Barclays
Fresenius Medical downgraded to Equal Weight from Overweight at Barclays
09/10/21 JPMorgan
Fresenius Medical downgraded to Underweight from Neutral at JPMorgan
08/11/21 JPMorgan
Fresenius Medical price target raised to EUR 61.30 from EUR 58.80 at JPMorgan
08/04/21 Societe Generale
Fresenius Medical price target raised to EUR 71 from EUR 64 at Societe Generale
SNY Sanofi
$48.22 /

+0.21 (+0.44%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
WAT Waters
$407.50 /

-2.335 (-0.57%)

08/04/21 SVB Leerink
Waters price target raised to $385 from $370 at SVB Leerink
08/04/21 Baird
Waters price target raised to $360 from $297 at Baird
08/04/21 Citi
Waters price target raised to $400 from $315 at Citi
07/06/21 Evercore ISI
Evercore ISI upgrades Waters to Outperform on turnaround progress
ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

08/27/21 BMO Capital
Alnylam price target raised to $196 from $174 at BMO Capital
08/04/21 Barclays
Alnylam price target raised to $216 from $196 at Barclays
08/04/21 Piper Sandler
Alnylam downgraded to Neutral from Overweight at Piper Sandler
06/30/21 Piper Sandler
Alnylam's zilebesiran has 'best in class' potential, says Piper Sandler
BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
08/10/21 Canaccord
Bluebird Bio downgraded to Hold from Buy at Canaccord
08/10/21 Mizuho
Bluebird Bio price target lowered to $29 from $70 at Mizuho
AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
FOLD Amicus
$11.02 /

-0.13 (-1.17%)

07/19/21 BTIG
Amicus assumed with a Buy at BTIG
07/09/21 Chardan
Amicus coverage transferred at Chardan
07/01/21 Berenberg
Amicus assumed with a Hold at Berenberg
05/27/21 Needham
Amicus initiated with a Hold at Needham
PFE Pfizer
$44.71 /

-0.06 (-0.13%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
PAHC Phibro Animal Health
$21.37 /

-0.03 (-0.14%)

08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
07/07/21 Barclays
Phibro Animal Health downgraded to Underweight from Equal Weight at Barclays
QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

07/14/21 Citi
Qiagen price target lowered to $58 from $65 at Citi
07/14/21 Kepler Cheuvreux
Qiagen downgraded to Hold from Buy at Kepler Cheuvreux
06/11/21 Berenberg
Qiagen price target lowered to EUR 54 from EUR 56 at Berenberg
06/03/21 Goldman Sachs
Qiagen initiated with a Neutral at Goldman Sachs
IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
WAT Waters
$407.50 /

-2.335 (-0.57%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

PAHC Phibro Animal Health
$21.37 /

-0.03 (-0.14%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

FOLD Amicus
$11.02 /

-0.13 (-1.17%)

EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

ATR AptarGroup
$123.60 /

-1.1 (-0.88%)

ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

SNY Sanofi
$48.22 /

+0.21 (+0.44%)

RHHBY Roche
$46.86 /

+0.11 (+0.24%)

QGEN Qiagen
$53.51 /

+0.02 (+0.04%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

FOLD Amicus
$11.02 /

-0.13 (-1.17%)

FMS Fresenius Medical
$35.25 /

-0.42 (-1.18%)

EXEL Exelixis
$20.31 /

-0.18 (-0.88%)

BLUE Bluebird Bio
$17.50 /

-0.29 (-1.63%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

ALNY Alnylam
$188.20 /

+0.595 (+0.32%)

ALLO Allogene Therapeutics
$24.58 /

-0.37 (-1.48%)

PFE Pfizer
$44.71 /

-0.06 (-0.13%)

IONS Ionis Pharmaceuticals
$36.23 /

-0.77 (-2.08%)

AZN AstraZeneca
$56.25 /

-0.21 (-0.37%)

Hot Stocks
Sanofi completes acquisition of Translate Bio » 09:27
09/14/21
09/14
09:27
09/14/21
09:27
SNY

Sanofi

$48.20 /

-0.135 (-0.28%)

, TBIO

Translate Bio

$37.37 /

-0.07 (-0.19%)

Sanofi announced the…

Sanofi announced the completion of its acquisition of Translate Bio, further accelerating the company's efforts to develop transformative vaccines and therapies using mRNA technology. The acquisition adds a critical pillar to the company's mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. The tender offer for all of the outstanding shares of Translate Bio common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, September 13, 2021. The minimum tender condition and all of the other conditions to the offer have been satisfied and on September 14, 2021, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn. Following its acceptance of the tendered shares, Sanofi completed its acquisition of Translate Bio through the merger of a wholly owned subsidiary of Sanofi with and into Translate Bio, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Translate Bio continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi. In connection with the merger, all Translate Bio shares not validly tendered in the tender offer have been converted into the right to receive the same $38 per share in cash, without interest thereon and net of any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. As of September 14, 2021, Translate Bio common stock will cease to be traded on the NASDAQ Global Select Stock Market.

ShowHide Related Items >><<
TBIO Translate Bio
$37.37 /

-0.07 (-0.19%)

SNY Sanofi
$48.20 /

-0.135 (-0.28%)

SNY Sanofi
$48.20 /

-0.135 (-0.28%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
TBIO Translate Bio
$37.37 /

-0.07 (-0.19%)

08/04/21 Roth Capital
Translate Bio price target lowered to $38 from $45 at Roth Capital
08/03/21 B. Riley
Direct read to Arcturus from Translate Bio deal 'unwarranted,' says B. Riley
08/03/21 Brookline
Brookline reiterates Buy on Arcturus amid RNA focus following Translate Bio deal
08/03/21 Jefferies
Translate Bio downgraded to Hold from Buy at Jefferies
TBIO Translate Bio
$37.37 /

-0.07 (-0.19%)

SNY Sanofi
$48.20 /

-0.135 (-0.28%)

SNY Sanofi
$48.20 /

-0.135 (-0.28%)

TBIO Translate Bio
$37.37 /

-0.07 (-0.19%)

SNY Sanofi
$48.20 /

-0.135 (-0.28%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.